ArticleIDCases2026
Inflammatory exacerbation of hepatic alveolar echinococcosis during dupilumab therapy: A case report.
Article in IDCases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Alveolar echinococcosis is a rare but potentially fatal parasitic disease characterized by slow, infiltrative hepatic growth. Disease progression is strongly influenced by host immune status, and atypical courses have been reported in immunocompromised individuals. Dupilumab, a monoclonal antibody targeting interleukin-4 and interleukin-13 signaling, is increasingly used for atopic diseases; however, its impact on latent helminth infections remains unclear. We report a case of hepatic alveolar echinococcosis with pleural involvement occurring during dupilumab therapy, suggesting a possible interaction between targeted immune modulation and disease behavior. Case presentation: A 29-year-old man presented with acute epigastric and left flank pain, fever, and inflammatory markers. Computed tomography revealed a calcified hepatic lesion protruding from the left lateral segment, accompanied by newly developed subdiaphragmatic and left pleural fluid collections suggestive of abscess formation. The patient had been receiving dupilumab for atopic dermatitis. Serological testing confirmed alveolar echinococcosis. Despite broad-spectrum antibiotic therapy, inflammation persisted, and surgical resection was performed, including partial hepatectomy with resection of the diaphragm and pleura. Histopathological examination demonstrated laminated parasitic structures consistent with echinococcal infection in hepatic and pleural tissues, without pulmonary parenchymal involvement. Postoperatively, the patient recovered well and was started on long-term antiparasitic therapy. Conclusions: This case highlights an inflammatory exacerbation of hepatic alveolar echinococcosis with pleural extension during dupilumab therapy. Although causality cannot be established, inhibition of type 2 immune pathways may be associated with atypical inflammatory manifestations of latent helminth infections. Clinicians should remain vigilant for inflammatory presentations when prescribing biologic agents, particularly in endemic regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.